Antibody drug conjugates (ADCs) are biotherapeutic agents composed of a monoclonal antibody covalently linked to a cytotoxic payload via a chemical linker. Their unique structure combines the dual advantages of antibody-mediated targeted delivery and the potent cytotoxicity, demonstrating remarkable clinical efficacy in solid tumors, hematological malignancies and other therapeutic areas. ADCs are expected to play a pivotal role in future global drug development. Throughout the entire lifecycle of ADC development, manufacturing, and quality control, their binding affinity and biological activity critically influence therapeutic efficacy and safety. Comprehensive characterization of in vitro biological activity not only serves as the cornerstone for ensuring the clinical performance but also drives the resolution of current technical challenges and the advancement of innovative drug development. This review systematically discusses the current in vitro biological activity evaluation methods of ADCs, focusing on five functional modules based on the mechanism of ADCs: target binding activity, internalization efficiency, payload cytotoxicity, bystander effect, and Fc-mediated functions, aiming to provide methodological references for ADC development and quality control.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |